BOPA 2018 | Changing the UK clinical trial infrastructure: accommodating the future
The past decade has seen great progress in terms of new and effective treatment for both malignant and non malignant cancers. The advent of genomics has led to better targeted therapy trials with smaller, specific cohorts. Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, calls attention to the high quality, reputable Phase III trials conducted in the UK, while still urging the acceleration of trials assessing novel therapies. Prof. Craddock also discusses the steps that have been taken to improve patient outcomes through clinical trials. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK.
Get great new content delivered to your inboxSign up